BTCY Company Profile and Key Details

Biotricity, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.15. This means the shares are trading below this model’s fair value.

Biotricity, Inc. (OTC:BTCY) closed at $0.30 USD, gaining $0.01 (3.48%) from the previous close of $0.29. The stock is currently mid-range between its 52-week high and low $0.23 and $0.83. With a market capitalization of about $8.34 million, Biotricity, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.37). Key stats such as the average daily volume over the past year has been around 68.02 thousand shares, volume is running light vs its 52-week average. Headquartered in Redwood City, CA, Biotricity, Inc. operates in the Healthcare sector and the Medical - Devices industry. Led by CEO Waqaas Al-Siddiq, the company employs approximately 55 people and listed since February 16, 2018. Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions primarily in the United States.

Our AI price prediction model suggests that Biotricity, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -1.89%, with price expected at $0.26 by February 24, 2026, within a range of $0.23 to $0.29 3-Month Outlook: Projected fall of -43.4%, reaching $0.15 by May 08, 2026, with a range of $0.13 to $0.17. 1-Year Outlook: Projected gain of 349.06%, with price at $1.19 by February 10, 2027, within a range of $0.00 to $0.77.

Biotricity, Inc. (NASDAQ:BTCY) shares are down -59.73% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Biotricity, Inc. trading at a premium to the broader market with a P/E of -1.74. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $4.33, suggesting 1533.96% upside. Our AI forecast model points to short-term weakness (-1.89% over two weeks), a medium-term fall (-43.4% over three months), and a longer-term gain (349.06% over one year), with expected trading ranges indicating moderate volatility.

Biotricity, Inc. trades at a P/E ratio of -1.74, slightly below the S&P 500 average, with a price-to-sales ratio of 0.55 and a price-to-book ratio of -0.24 indicating negative book value, which may reflect financial stress. The P/FCF stands at -18.67, also below market averages.